Bocunebart

Bocunebart is a humanized monoclonal antibody designed to target human ADCYAP1, also known as adenylate cyclase-activating polypeptide (PACAP). By specifically binding to ADCYAP1, Bocunebart effectively inhibits the associated inflammatory signaling pathways, exhibiting potent anti-inflammatory activity. This antibody is particularly valuable for research focused on inflammation-related diseases, offering significant insights into the modulation of inflammatory responses.

In Stock

Product Details

Manufacturer Adooq Bioscience
CAS Number 2984605-64-1

Storage

Store lyophilized at -20°C, keep desiccated.
In lyophilized form, the antibody is stable for 36 months.
After reconstitution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Customer Questions
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research. Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
Loading...

Added to your cart

View Cart Checkout
Loading...